Építés alatt – nem éles oldal
Belépés
Még nem keres résztvevőt itt: Kína4. fázis

Evaluating the Efficacy and Safety of Daridorexant Transition From BZRAs in Insomnia Patients(EASY-TIP)

A legfontosabb adatok

Ki végzi
Xuanwu Hospital, Beijing
Hol
Beijing (Kína)A helyszín megnézése
Azonosító
Állapot
Toborzás még nem indult
Fázis
4. fázis
Résztvevők
156 fő, tervezett
Kezdés
2026. aug. 1.
Várható befejezés
2030. dec. 1.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Daridorexant
A regiszteradat frissítve
2026. július 29.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with insomnia who take one BZRA sleep medicine and need a change. They switch to daridorexant while slowly stopping the BZRA.

Életkor
18 to 70 years
Nem
All sexes
A betegség stádiuma
Insomnia disorder by DSM-5 criteria, with symptoms ≥3 times per week for ≥3 months. Insomnia for no more than 5 years. Spending at least 7 hours in bed each night. HAMA-14 anxiety score <14 and HAMD-17 depression score <17.
Korábbi kezelés
Must have taken one BZRA alone at a stable dose for at least 3 nights per week in the month before joining. The current treatment did not work well enough or was not tolerated. BZRA use for less than 3 years and no more than 5 nights per week.

A részvétel fő kizáró okai

  • Other sleep disorders, or daytime naps ≥1 hour/day on ≥3 days/week
  • BZRA dose above the highest dose in the package insert, or use of two or more BZRAs in the past 3 months
  • Past lack of response to orexin receptor antagonists such as daridorexant, lemborexant or suvorexant
  • Severe mental illness in the past 6 months, suicidal thoughts or behavior, or severe alcohol or drug misuse in the past 2 years
  • Pregnancy, breastfeeding, planned pregnancy within 90 days, or severe liver problems (Child-Pugh score ≥10)

A regiszter feltételei, szó szerint

Mind a 28 feltétel megnézéseKevesebb

Ki vehet részt

  • Male or female, aged ≥18 and ≤70 years
  • Meet DSM-5 diagnostic criteria for insomnia disorder: dissatisfaction with nighttime sleep despite adequate sleep opportunity, manifested as difficulty initiating sleep, difficulty maintaining sleep (frequent awakenings or difficulty returning to sleep after awakening), or early-morning awakening with inability to resume sleep, accompanied by subjective experience of daytime dysfunction. Symptoms occur ≥3 times per week and persist for ≥3 months
  • Received stable BZRA monotherapy for at least 3 nights per week during the 1 month prior to enrollment
  • Bedtime duration of no less than 7 hours per night
  • Unsatisfactory response or intolerance to current therapy, with clinical need to adjust insomnia medication regimen
  • Hamilton Anxiety Rating Scale (HAMA-14) score <14
  • Hamilton Depression Rating Scale (HAMD-17) score <17
  • Willing and able to comply with the study protocol and provide written informed consent

Ki nem vehet részt

  • Concurrent use of two or more BZRAs within the past 3 months
  • Initiation of cognitive behavioral therapy for insomnia (CBT-I) within 1 month prior to Visit 1
  • Prior non-response to orexin receptor antagonists (daridorexant, lemborexant, suvorexant, etc.)
  • Unable to discontinue strong CYP3A4 inhibitors and strong or moderate CYP3A4 inducers during the study
  • Other sleep disorders such as narcolepsy-related symptoms, restless legs syndrome, circadian rhythm sleep disorder, REM sleep behavior disorder, etc
  • Clinically significant disease (e.g., cardiac, respiratory, gastrointestinal, renal) that may affect participant safety or interfere with study assessments, as judged by the investigator. Participants for whom sedative medications are contraindicated due to occupational or safety reasons are also excluded
  • Severe psychiatric disorder within the past 6 months, or severe alcohol/substance abuse/dependence within the past 2 years
  • History of hypersensitivity to any component of daridorexant tablets
  • Severe hepatic impairment (Child-Pugh score ≥10)
  • History of chronic insomnia >5 years
  • History of BZRA treatment ≥3 years
  • Daytime napping ≥1 hour/day and ≥3 days/week
  • Daily BZRA dose exceeding the maximum recommended dose for insomnia treatment per package insert
  • BZRA use >5 nights per week
  • Use of central nervous system depressants within the past 3 months
  • Use of long-acting sedative-hypnotics (e.g., clonazepam) within the past 3 months
  • Use of anxiolytics or antidepressants for off-label insomnia treatment within the past 3 months
  • Active suicidal ideation or behavior within the past 6 months
  • Pregnancy, lactation, or planned pregnancy within 90 days
  • Unable to avoid excessive alcohol consumption during the study

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 70 év között vagy?

Helyszínek itt: Kína

  • Xuanwu Hospital, Capital Medical UniversityBeijing, KínaContact: Shuqin ZhanToborzás még nem indult

A vizsgálatról

Mit akar kideríteni a vizsgálat

Brief Summary:

A teljes eredeti leírásKevesebb

This study is a prospective, multicenter, open-label cohort study designed to evaluate the efficacy and safety of transitioning adult patients with insomnia from benzodiazepine receptor agonists (BZRAs) to daridorexant.

A total of 156 participants will be enrolled. The study consists of a 1-week baseline phase and a 9-week daridorexant treatment phase. During the treatment phase, daridorexant 50 mg is initiated once daily while BZRAs are gradually tapered and discontinued based on individual patient response.

The primary outcome is the proportion of patients who successfully transition from BZRAs to daridorexant at Week 5, defined as a ≥50% reduction or complete discontinuation of the original BZRA dose, with continued willingness to take daridorexant and no withdrawal due to worsening insomnia or adverse events. Secondary outcomes include changes in Insomnia Severity Index (ISI) scores and patient-reported sleep outcomes.

This study aims to provide real-world evidence for the safe and effective transition from BZRAs to daridorexant in clinical practice.

A vizsgálat csoportja

  • Daridorexant Transition GroupA vizsgált kezelés

    Participants receive daridorexant 50 mg orally once nightly for 9 weeks, with gradual tapering and discontinuation of their prior benzodiazepine receptor agonist (BZRA) therapy based on individual clinical response. Dose reduction of daridorexant to 25 mg is permitted if clinically indicated. The study includes 6 visits over 10 weeks, with the primary endpoint assessed at Week 5.

    Kezelés: Daridorexant

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Illeszkedési kérdések
Forrás: NCT07733414: ki vehet részt
A regiszteradat frissítve
2026. július 29.